Page 3 of 19

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claim 1. (Currently amended) A compound represented by the general formula I

HN
$$R^5$$
 R^4 R^3 R^5 R^6 R^7 R^8

wherein

 R^1 , R^2 , R^3 , R^4 , R^5 are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yloxy, erand NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, erand NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, erand C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; or

R² and R³ together form a heterocycle fused to with the the phenyl ring selected from to which they are attached form the structure represented by the formula

Page 4 of 19

 R^6 , R^7 , R^8 , R^9 are independently selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yloxy, er and R^8 wherein R^8 and R^9 are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, er and R^8 - C_{1-6} -alk(en/yn)yl, wherein R^8 and R^8 are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, er and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^8 and R^9 together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom;

provided that at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ is different from hydrogen; also provided that when R³ is methyl or methoxy, then at least one of R¹, R², R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ is different from hydrogen; or a pharmaceutically acceptable salt thereof.

Claim 2. (Currently amended) The compound of claim 1, wherein R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, halo- C_{1-6} -alk(en/yn)yl, and of NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, and of NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently

Page 5 of 19

selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and er C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w - C_{1-6} -alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and er C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; typically, R^4 -is selected from hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -alkyloxy, or halo- C_{1-6} -alkyl; more typically, R^4 -is selected from hydrogen, C_{1-6} -alkyl, or halogen.

Claim 3. (Currently amended) The compound of any one of claims 1-2 claim 1, wherein R^2 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^2 is selected from hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl; more typically, R^2 is selected from hydrogen, or C_{1-6} -alkoxy.

Claim 4. (Currently amended) The compound of any one of claims 1-3 claim 1, wherein R^3 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^3 is selected from hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, or halogen.

Claim 5. (Currently amended) The compound of any one of claims 1-2 claim 1, wherein R² and R³ together form a heterocycle fused to with the phenyl ring selected from to which they are attached form the structure represented by the formula

Page 6 of 19

$$\mathbb{R}^{5}$$
 \mathbb{R}^{4}
 \mathbb{R}^{5}
 \mathbb{R}^{1}

Claim 6. (Currently amended) The compound of any one of claims 1–5 claim 1 wherein R^4 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^4 -is selected from hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl, or halo- C_{1-6} -alkyl; more typically, R^4 -is selected from hydrogen, or C_{1-6} -alkoxy.

Claim 7. (Currently amended) The compound of any one of claims 1-6 claim 1 wherein R^5 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, halo- C_{1-6} -alk(en/yn)yl, or and R^2 wherein R^2 and R^2 are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, or and R^2 and R^2 are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, or and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^2 and R^2 is R^2 or R^2 or R^2 and R^2 is R^2 or R^2 or R^2 and R^2 is selected from the group consisting of hydrogen, R^2 and R^2 or R^2 a

Page 7 of 19

Claim 8. (Currently amended) The compound of any one of claims 1-7 claim 1 wherein R^6 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^6 is selected from hydrogen, or halogen.

Claim 9. (Currently amended) The compound of any one of claims 1-8 claim 1 wherein R^7 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^7 is selected from hydrogen, or halogen.

Claim 10. (Currently amended) The compound of any one of claims 1-9 claim 1 wherein R^8 is selected from the group consisting of hydrogen, halogen, $C_{1.6}$ -alk(en/yn)yl, halo- $C_{1.6}$ -alk(en/yn)yl, or and NR x R y wherein R^x and R^y are independently selected from the group consisting of hydrogen, $C_{1.6}$ -alk(en/yn)yl, cyano- $C_{1.6}$ -alk(en/yn)yl, $C_{3.8}$ -cycloalk(en)yl, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, or and NR z R w - $C_{1.6}$ -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, $C_{1.6}$ -alk(en/yn)yl, $C_{3.8}$ -cycloalk(en)yl, or and $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, provided that if one of R^x and R^y is NR z R w - $C_{1.6}$ -alk(en/yn)yl, cyano- $C_{1.6}$ -alk(en/yn)yl, $C_{3.8}$ -cycloalk(en)yl, or and $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, cyano- $C_{1.6}$ -alk(en/yn)yl, $C_{3.8}$ -cycloalk(en)yl, or and $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; typically, R^8 is selected from hydrogen, $C_{1.6}$ -alkyl, halogen, halo $C_{1.6}$ -alkyl, or NR x R y wherein R^x is hydrogen and R^y is $C_{1.6}$ -alkyl, more typically, R^8 is selected from hydrogen, $C_{1.6}$ -alkyl, halogen, or halo- $C_{1.6}$ -alkyl,

Claim 11. (Currently amended) The compound of any one of claims 1-10 claim 1 wherein R^9 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; typically, R^9 -is selected from hydrogen.

Claim 12. (Currently amended) The compound of any one of claims 1-11 claim 1 wherein the compound of formula I has 1-4 substituents in the phenyl ring(s), selected

Page 8 of 19

from any one of R¹-R⁹, which are different from hydrogen, and the remaining substituents are hydrogen.

- Claim 13. (Currently amended) The <u>A</u>compound of claim 1, said compound being selected from the group consisting of:
- 4-[2-(4-Fluorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Methoxyphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-(5-Methyl-2-p-tolylsulfanylphenyl)-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Fluorophenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chlorophenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chlorophenylsulfanyl)-5-trifluoromethyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Fluoro-2-methylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chlorophenylsulfanyl)-4-fluoro-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[4-Fluoro-2-(p-tolylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[4-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2,4-Dimethylphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2,4-Dimethylphenylsulfanyl)-5-trifluoromethyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-(2-p-Tolylsulfanyl-5-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Fluoro-2-methylphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[5-Bromo-2-(2,4-dimethylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chlorophenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[5-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2,4-Dichlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(3-Methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[3-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2-Chlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2-Chloro-4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,

Page 9 of 19

- 4-[2-(2-Fluorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(2-Bromophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Bromophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-(2-o-Tolylsulfanylphenyl)-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Chloro-2-methylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
- 4-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3,4-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Methoxy-5-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Methoxy-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Fluoro-4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2.4-Dimethyl-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-(5-Fluoro-2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-(2-m-Tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Fluoro-3-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Bromo-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,4-Dichloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,4-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Chloro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Fluoro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,4-Difluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Bromo-4-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,

Page 10 of 19

- 4-[2-(2-Bromo-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-(5-Methyl-2-o-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Methoxy-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Fluoro-4-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3,4-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Fluoro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3,4-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Bromo-2-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Bromo-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,4-Difluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Bromo-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Chloro-2-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(2-fluoro-4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-methoxy-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine.
- 4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(4-methoxy-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Dimethyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Methyl-2-(3-methyl-phenylsulfanyl)--phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3.4-Dimethyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Chloro-2-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Difluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Difluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,

Page 11 of 19

- 4-[2-(3-Chloro-2-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Fluoro-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Fluoro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Methyl-2-(3-trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Ethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Ethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-tert-Butyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-tert-Butyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Trifluoromethoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3,5-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,5-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,5-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3,5-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,4,6-Trimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Methylamino-2-(4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(2-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-(5-Fluoro-2-o-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
- 4-(5-Fluoro-2-p-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,

Page 12 of 19

- 4-[2-(Benzo[1,3]dioxol-5-ylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-4-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2,3-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(Benzo[1,3]dioxol-5-ylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(3-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-(5-Fluoro-2-m-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
- 4-[5-Fluoro-2-(3-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Chloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(2-Chloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[4-Fluoro-2-(4-methyl- phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Bromo-2-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(4-Fluoro-3-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
- 4-[2-(3-Fluoro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine, and
- 4-[5-Fluoro-2-(4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine[[,]]; or a pharmaceutically acceptable salt thereof.
- Claim 14. (Currently amended) A pharmaceutical composition comprising a compound of any one of claims 1-13 claim 1 or a pharmaceutically acceptable acid-addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

Claim 15. (Cancelled)

Claim 16. (Currently amended) A method for the treatment of an affective disorder, such as depression, anxiety disorder[[s]] including general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia in a living animal body, including a human, comprising administering to a subject a

Ask Püschl, et al. Appln No: 10/551,869

Filed: September 30, 2005

Page 13 of 19

therapeutically effective amount of a compound of any one of claims 1- 13 claim 1 or a pharmaceutically acceptable acid addition salt thereof.

Claim 17. (Cancelled)

Claim 18. (New) The compound of claim 2 wherein R^1 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -alkyloxy, and halo- C_{1-6} -alkyl.

Claim 19. (New) The compound of claim 18 wherein R^1 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, and halogen

Claim 20. (New) The compound of claim 3 wherein R^2 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl.

Claim 21. (New) The compound of claim 20 wherein R^2 is selected from the group consisting of hydrogen and C_{1-6} -alkoxy.

Claim 22. (New) The compound of claim 4 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen, C_{1-6} -alkylsulfanyl, halo- C_{1-6} -alkyloxy.

Claim 23. (New) The compound of claim 22 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, and halogen.

Claim 24. (New) The compound of claim 6 wherein R^4 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl.

Claim 25. (New) The compound of claim 24 wherein R^4 is selected from the group consisting of hydrogen and C_{1-6} -alkoxy.

Page 14.of 19

Claim 26. (New) The compound of claim 7 wherein R^5 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -alkyloxy, and halo- C_{1-6} -alkyl.

Claim 27. (New) The compound of claim 26 wherein R^5 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, and halogen.

Claim 28. (New) The compound of claim 8 wherein R⁶ is selected from the group consisting of hydrogen and halogen.

Claim 29. (New) The compound of claim 9 wherein R⁷ is selected from the group consisting of hydrogen and halogen.

Claim 30. (New) The compound of claim 10 wherein R^8 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, halo- C_{1-6} -alkyl, and NR^xR^y wherein R^x is hydrogen and R^y is C_{1-6} -alkyl.

Claim 31. (New) The compound of claim 30 wherein R^8 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, and halo- C_{1-6} -alkyl.

Claim 32. (New) The compound of claim 11 wherein R⁹ is hydrogen.

Claim 33. (New) The method of claim 16 wherein the affective disorder is depression.

Claim 34. (New) A method for the treatment of an anxiety disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Claim 35. (New) The method of claim 34 wherein the anxiety disorder is selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic

Ask Püschl, et al.

Appln No: 10/551,869

Filed: September 30, 2005

Page 15 of 19

stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific

phobias, social phobia and agoraphobia.

Claim 36. (New) A pharmaceutical composition comprising a compound of claim 13 or

a pharmaceutically acceptable salt thereof and at least one pharmaceutically

acceptable carrier or diluent.

Claim 37. (New) A method for the treatment of an affective disorder comprising

administering to the subject a therapeutically effective amount of a compound of claim

13 or a pharmaceutically acceptable salt thereof.

Claim 38. (New) The method of claim 37 wherein the affective disorder is depression.

Claim 39. (New) A method for the treatment of an anxiety disorder comprising

administering to the subject a therapeutically effective amount of a compound of claim

13 or a pharmaceutically acceptable salt thereof.

Claim 40. (New) The method of claim 39 wherein the anxiety disorder is selected from

the group consisting of general anxiety disorder, social anxiety disorder, post traumatic

stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific

phobias, social phobia and agoraphobia.